In a phase I trial of patients with AML/MDS, Lyt-200 treatment alone or combined with the PD-1 ICI Tislelizumab (BeiGene) or the chemotherapeutics gemcitabine and nab-paclitaxel (Table 1) was well-tolerated and showed anti-tumor activity [226]. This evidence concerns the gene PDCD1 and acute myeloid leukemia.